BRIEF,O
COMMUNICATION,O
Chronic,O
heart,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
as,O
the,O
most,O
prevalent,O
comorbidities,O
among,O
deaths,O
by,O
COVID,O
‐,O
19,NUMBER
in,O
Brazil,COUNTRY
Julianne,O
Pachie,O
‐,O
ga,O
1,NUMBER
.,O
Alexandre,PERSON
Jos,PERSON
dos,PERSON
Santos,PERSON
Afonso,PERSON
1,NUMBER
.,O
Gssica,O
Thas,O
Sinhorin,O
1,NUMBER
.,O
Bianca,PERSON
Teshima,PERSON
de,PERSON
Alencar,PERSON
2,NUMBER
.,O
Marta,ORGANIZATION
dos,ORGANIZATION
Santos,ORGANIZATION
Miranda,ORGANIZATION
de,ORGANIZATION
Arajo,ORGANIZATION
3,NUMBER
.,O
Fabiana,PERSON
Gulin,PERSON
Longhi,PERSON
4,NUMBER
.,O
Andernice,ORGANIZATION
dos,ORGANIZATION
Santos,ORGANIZATION
Zanetti,ORGANIZATION
3,NUMBER
.,O
Omar,PERSON
Ariel,PERSON
Espinosa,PERSON
5,NUMBER
Universidade,ORGANIZATION
do,ORGANIZATION
Estado,ORGANIZATION
de,ORGANIZATION
Mato,ORGANIZATION
Grosso,ORGANIZATION
.,O
Faculdade,PERSON
de,PERSON
Cincias,PERSON
da,PERSON
Sade,PERSON
.,O
Departamento,ORGANIZATION
de,ORGANIZATION
Medicina,ORGANIZATION
.,O
Cceres,LOCATION
.,O
Mato,PERSON
Grosso,PERSON
.,O
Brazil,COUNTRY
Universidade,ORGANIZATION
do,ORGANIZATION
Estado,ORGANIZATION
de,ORGANIZATION
Mato,ORGANIZATION
Grosso,ORGANIZATION
.,O
Faculdade,PERSON
de,PERSON
Cincias,PERSON
da,PERSON
Sade,PERSON
.,O
Departamento,ORGANIZATION
de,ORGANIZATION
Enfermagem,ORGANIZATION
.,O
Cceres,LOCATION
.,O
Mato,PERSON
Grosso,PERSON
.,O
Brazil,COUNTRY
Universidade,ORGANIZATION
do,ORGANIZATION
Estado,ORGANIZATION
de,ORGANIZATION
Mato,ORGANIZATION
Grosso,ORGANIZATION
.,O
Faculdade,PERSON
de,O
Cincias,O
Agrrias,O
e,O
Biolgicas,LOCATION
.,O
Programa,O
de,O
Ps,O
‐,O
Graduao,O
em,O
Cincias,O
Ambientais,O
.,O
Cceres,PERSON
.,O
Mato,PERSON
Grosso,PERSON
.,O
Brazil,COUNTRY
Age,O
.,O
sex,O
and,O
presence,O
of,O
comorbidities,O
are,O
risk,O
factors,O
associated,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
Hyper,O
‐,O
tension,O
.,O
diabetes,CAUSE_OF_DEATH
and,O
heart,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
are,O
the,O
most,O
common,O
comor,O
‐,O
bidities,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
estimate,O
the,O
prevalence,O
of,O
patients,O
with,O
comorbidities,O
who,O
died,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
Brazil,COUNTRY
.,O
Searches,O
of,O
data,O
were,O
carried,O
out,O
on,O
the,O
method,O
was,O
used,O
to,O
calculate,O
the,O
prevalence,O
of,O
patients,O
with,O
comorbidities,O
who,O
died,O
.,O
From,O
the,O
beginning,O
of,O
the,O
pandemic,O
in,O
Brazil,COUNTRY
until,O
May,DATE
20,DATE
.,DATE
2020,DATE
.,O
276.703,NUMBER
cases,O
of,O
COVID,O
‐,O
19,NUMBER
were,O
noti,O
‐,O
fied,O
in,O
Brazil,COUNTRY
.,O
6.4,PERCENT
%,PERCENT
died,O
.,O
58.6,PERCENT
%,PERCENT
of,O
whom,O
were,O
male,O
.,O
The,O
preva,O
‐,O
lence,O
of,O
comorbidities,O
among,O
deaths,O
was,O
83,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
CI,O
:,O
79,NUMBER
‐,O
87,NUMBER
),O
.,O
with,O
heart,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
and,O
diabetes,CAUSE_OF_DEATH
being,O
the,O
most,O
prevalent,O
.,O
To,O
our,O
knowledge,O
.,O
this,O
study,O
represents,O
the,O
first,ORDINAL
large,O
analysis,O
of,O
cas,O
‐,O
es,O
of,O
patients,O
with,O
confirmed,O
COVID,O
‐,O
19,NUMBER
in,O
Brazil,COUNTRY
.,O
There,O
is,O
a,O
high,O
prevalence,O
of,O
comorbidities,O
(,O
83,PERCENT
%,PERCENT
),O
among,O
patients,O
who,O
died,O
from,O
COVID,O
‐,O
19,NUMBER
in,O
Brazil,COUNTRY
.,O
with,O
heart,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
being,O
the,O
most,O
prevalent,O
.,O
This,O
is,O
important,O
considering,O
the,O
possible,O
secondary,O
effects,O
pro,O
‐,O
duced,O
by,O
drugs,CRIMINAL_CHARGE
such,O
as,O
hydroxychloroquine,O
.,O
KEYWORDS,O
:,O
COVID,O
‐,O
19,NUMBER
.,O
Prevalence,O
.,O
Deaths,O
.,O
Comorbidities,O
.,O
Brazil,COUNTRY
.,O
Heart,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
.,O
Centro,PERSON
de,O
Excelncia,O
do,O
Instituto,PERSON
Joanna,PERSON
Briggs,PERSON
.,O
Centro,PERSON
Brasileiro,PERSON
para,O
o,O
Cuidado,PERSON
Sade,O
Informado,O
por,O
Evidncias,O
.,O
So,O
Paulo,O
.,O
So,O
Paulo,O
.,O
Brazil,COUNTRY
Facul,O
‐,O
dade,O
do,O
Pantanal,O
.,O
Cceres,PERSON
.,O
Mato,PERSON
Grosso,PERSON
.,O
Brazil,COUNTRY
Correspondence,O
to,O
:,O
Omar,PERSON
Ariel,PERSON
Espinosa,PERSON
Faculdade,PERSON
do,O
Pantanal,O
.,O
Av,O
.,O
So,O
Luiz,PERSON
.,O
2522,DATE
.,O
CEP,O
78200,NUMBER
‐,O
000,NUMBER
.,O
Cceres,PERSON
.,O
MT,STATE_OR_PROVINCE
.,O
Brazil,COUNTRY
The,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
pandemic,O
has,O
infected,O
more,O
than,O
seven,NUMBER
million,NUMBER
people,O
worldwide,O
in,O
216,NUMBER
countries,O
.,O
and,O
.,O
until,O
Jun,DATE
16,DATE
.,DATE
2020,DATE
.,O
it,O
had,O
caused,O
over,O
four,NUMBER
hundred,NUMBER
thousand,NUMBER
deaths1,O
.,O
Its,O
etiological,O
agent,O
is,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
.,O
transmitted,O
by,O
contact,O
with,O
an,O
infected,O
person,O
or,O
contam,O
‐,O
inated,O
fluids2,O
.3,O
.,O
A,O
multicenter,O
cohort,O
study,O
showed,O
that,O
gender,O
and,O
advanced,O
age,O
are,O
significantly,O
correlated,O
with,O
COVID,O
‐,O
19,NUMBER
and,O
these,O
findings,O
are,O
consistent,O
with,O
the,O
higher,O
incidence,O
among,O
older,O
people,O
and,O
men4,O
.,O
Another,O
study,O
observed,O
that,O
the,O
presence,O
of,O
any,O
comorbidity,O
increases,O
the,O
patients,O
risk,O
of,O
developing,O
res,O
‐,O
piratory,O
distress,O
.,O
possibly,O
leading,O
to,O
an,O
intensive,O
care,O
unit,O
(,O
ICU,O
),O
hospitalization,O
and,O
/,O
or,O
death5,O
.6,O
.,O
Cardiovascular,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
.,O
diabetes,CAUSE_OF_DEATH
.,O
hypertension,CAUSE_OF_DEATH
.,O
and,O
chronic,CAUSE_OF_DEATH
obstructive,CAUSE_OF_DEATH
pulmonary,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
are,O
among,O
the,O
most,O
prevalent,O
comorbidities,O
in,O
COVID,O
‐,O
19,NUMBER
In,O
Brazil,COUNTRY
.,O
the,O
first,ORDINAL
confirmed,O
case,O
of,O
COVID,O
‐,O
19,NUMBER
was,O
reported,O
on,O
February,DATE
26,DATE
.,O
20208,NUMBER
.,O
and,O
the,O
first,ORDINAL
known,O
death,O
was,O
reported,O
20,DATE
days,DATE
later,DATE
.,O
on,O
March,DATE
17,DATE
.,O
Until,O
Pachiega,O
et,O
al,O
.,O
June,DATE
21,DATE
.,O
the,O
country,O
had,O
con,O
‐,O
firmed,O
1.073.376,NUMBER
cases,O
and,O
50.182,NUMBER
deaths,O
.,O
with,O
an,O
incidence,O
of,O
5.08,NUMBER
cases,O
per,O
million,NUMBER
This,O
study,O
aimed,O
to,O
estimate,O
the,O
preva,O
‐,O
lence,O
of,O
patients,O
with,O
comorbidities,O
that,O
died,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
the,O
Brazilian,NATIONALITY
Federative,O
Units,O
.,O
Data,O
were,O
extracted,O
from,O
the,O
bul,O
‐,O
letin,O
on,O
the,O
epidemiological,O
situation,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
made,O
avail,O
‐,O
able,O
by,O
each,O
of,O
the,O
26,NUMBER
Brazilian,NATIONALITY
States,LOCATION
and,O
the,O
Federal,O
District,O
.,O
on,O
their,O
official,O
websites,O
.,O
The,O
obtained,O
data,O
were,O
evaluated,O
ac,O
‐,O
cording,O
to,O
the,O
following,O
variables,O
:,O
confirmed,O
cases,O
.,O
ICU,O
hospi,O
‐,O
talizations,O
and,O
deaths,O
.,O
The,O
epidemiological,O
and,O
clinical,O
profiles,O
of,O
the,O
deaths,O
cases,O
were,O
also,O
described,O
.,O
considering,O
sex,O
.,O
age,O
.,O
and,O
the,O
presence,O
and,O
type,O
of,O
comorbidities,O
.,O
respectively,O
.,O
Be,O
‐,O
cause,O
not,O
all,O
States,O
reported,O
the,O
presence,O
of,O
comorbidities,O
in,O
fatal,O
cases,O
.,O
the,O
random,O
‐,O
effects,O
model,TITLE
to,O
estimate,O
the,O
pooled,O
prevalence,O
of,O
comorbidities,O
in,O
deaths,O
and,O
their,O
respective,O
confi,O
‐,O
dence,O
intervals,O
(,O
CI,O
),O
of,O
95,PERCENT
%,PERCENT
.,O
was,O
used,O
.,O
The,O
heterogeneity,O
of,O
prevalence,O
was,O
analyzed,O
by,O
State,ORGANIZATION
using,O
the,O
Higgins,O
test,O
(,O
I2,O
),O
.,O
which,O
presents,O
the,O
percentage,O
of,O
variation,O
across,O
them,O
.,O
These,O
analyses,O
were,O
performed,O
using,O
the,O
Stata,O
statistical,O
software,O
.,O
version,O
12,NUMBER
(,O
Stata,ORGANIZATION
Corp,ORGANIZATION
LLC,ORGANIZATION
.,O
Texas,STATE_OR_PROVINCE
.,O
USA,COUNTRY
),O
.,O
Data,O
collection,O
from,O
the,O
official,O
websites,O
of,O
each,O
State,ORGANIZATION
Health,ORGANIZATION
Department,ORGANIZATION
took,O
place,O
from,O
the,O
beginning,O
of,O
the,O
pandemic,O
in,O
Brazil,COUNTRY
to,O
May,DATE
20,DATE
.,DATE
2020,DATE
.,O
During,O
this,O
period,O
.,O
we,O
found,O
276.703,NUMBER
reported,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
among,O
which,O
11.278,NUMBER
(,O
4.8,PERCENT
%,PERCENT
),O
were,O
admitted,O
to,O
ICU,O
.,O
and,O
17.752,NUMBER
(,O
6.4,PERCENT
%,PERCENT
),O
cases,O
resulted,O
in,O
deaths,O
.,O
When,O
analyzing,O
ICU,O
hospitalization,O
percentage,O
by,O
State,ORGANIZATION
.,O
Rio,CITY
de,CITY
Janeiro,CITY
(,O
23.3,PERCENT
%,PERCENT
),O
and,O
Minas,ORGANIZATION
Gerais,ORGANIZATION
(,O
19.6,PERCENT
%,PERCENT
),O
The,COUNTRY
States,COUNTRY
with,O
the,O
highest,O
death,O
percentages,O
were,O
:,O
Rio,PERSON
de,PERSON
Janeiro,PERSON
(,O
10.7,PERCENT
%,PERCENT
),O
.,O
Para,O
(,O
9.4,PERCENT
%,PERCENT
),O
.,O
Sao,CITY
Paulo,CITY
(,O
7.8,PERCENT
%,PERCENT
),O
.,O
Pernambuco,LOCATION
(,O
8.1,PERCENT
%,PERCENT
),O
.,O
Amazonas,ORGANIZATION
(,O
6.9,PERCENT
%,PERCENT
),O
and,O
Parana,CITY
(,O
5.2,PERCENT
%,PERCENT
),O
.,O
Regarding,O
the,O
epi,O
‐,O
demiological,O
profile,O
of,O
fatal,O
cases,O
.,O
22,NUMBER
States,O
segregated,O
a,O
total,O
of,O
7.531,NUMBER
cases,O
by,O
sex,O
.,O
of,O
which,O
58.6,PERCENT
%,PERCENT
were,O
male,O
and,O
41.4,PERCENT
%,PERCENT
female,O
.,O
The,O
age,O
of,O
the,O
death,O
cases,O
was,O
reported,O
only,O
in,O
epidemiological,O
bulletins,O
of,O
25,NUMBER
States,O
.,O
From,O
17.752,NUMBER
cases,O
of,O
death,O
.,O
only,O
in,O
14.728,NUMBER
(,O
83,PERCENT
%,PERCENT
),O
the,O
age,O
was,O
reported,O
.,O
the,O
population,O
over,O
60,DURATION
years,DURATION
the,O
clinical,O
profile,O
was,O
only,O
reported,O
in,O
2.116,NUMBER
deaths,O
(,O
12,PERCENT
%,PERCENT
),O
from,O
15,NUMBER
States,O
.,O
1.768,NUMBER
of,O
which,O
presented,O
comorbidities,O
.,O
The,O
clinical,O
descriptions,O
of,O
the,O
comorbidities,O
in,O
the,O
death,O
cases,O
were,O
ex,O
‐,O
tracted,O
from,O
the,O
epidemiological,O
bulletins,O
of,O
each,O
State,ORGANIZATION
.,O
which,O
reported,O
diseases,CAUSE_OF_DEATH
grouped,O
according,O
to,O
:,O
Chronic,O
Heart,CAUSE_OF_DEATH
Diseases,CAUSE_OF_DEATH
.,O
Diabetes,CAUSE_OF_DEATH
.,O
Chronic,O
Lung,O
Diseases,CAUSE_OF_DEATH
(,O
including,O
Chronic,O
Obstructive,O
Pulmonary,O
Disease,CAUSE_OF_DEATH
and,O
asthma,CAUSE_OF_DEATH
),O
.,O
Chronic,O
Kidney,O
Diseases,CAUSE_OF_DEATH
.,O
Stroke,CAUSE_OF_DEATH
.,O
Hypertension,CAUSE_OF_DEATH
.,O
Obesity,O
.,O
Immunosuppressive,O
Diseases,CAUSE_OF_DEATH
.,O
Chronic,O
Liver,O
Diseases,CAUSE_OF_DEATH
.,O
Cancer,CAUSE_OF_DEATH
.,O
Digestive,O
System,O
Diseases,CAUSE_OF_DEATH
.,O
Pneumonia,CAUSE_OF_DEATH
.,O
Hemato,O
‐,O
logical,O
diseases,CAUSE_OF_DEATH
.,O
Tuberculosis,CAUSE_OF_DEATH
.,O
Metabolic,O
Diseases,CAUSE_OF_DEATH
(,O
different,O
than,O
diabetes,CAUSE_OF_DEATH
),O
.,O
Smoking,CAUSE_OF_DEATH
habit,O
.,O
Others,O
(,O
not,O
specified,O
),O
.,O
Among,O
the,O
cases,O
of,O
death,O
.,O
that,O
showed,O
one,NUMBER
or,O
more,O
previous,O
diseases,CAUSE_OF_DEATH
.,O
a,O
to,O
‐,O
tal,O
of,O
14.737,NUMBER
comorbidities,O
were,O
recorded,O
.,O
The,O
most,O
prevalent,O
co,O
‐,O
morbidities,O
found,O
were,O
:,O
35,PERCENT
%,PERCENT
chronic,O
heart,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
.,O
28.7,PERCENT
%,PERCENT
dia,O
‐,O
betes,O
.,O
8.2,PERCENT
%,PERCENT
chronic,O
lung,O
diseases,CAUSE_OF_DEATH
(,O
including,O
asthma,CAUSE_OF_DEATH
and,O
Chronic,O
Obstructive,O
Pulmonary,O
Disease,CAUSE_OF_DEATH
),O
.,O
5.9,PERCENT
%,PERCENT
kidney,O
diseases,CAUSE_OF_DEATH
.,O
5.3,PERCENT
%,PERCENT
stroke,O
.,O
5.1,PERCENT
%,PERCENT
hypertension,CAUSE_OF_DEATH
.,O
4.4,PERCENT
%,PERCENT
obesity,O
.,O
and,O
3.8,PERCENT
%,PERCENT
To,O
our,O
knowl,O
‐,O
edge,O
.,O
this,O
study,O
represents,O
the,O
first,ORDINAL
large,O
analysis,O
of,O
cases,O
of,O
sequentially,O
patients,O
with,O
confirmed,O
COVID,O
‐,O
19,NUMBER
in,O
Brazil,COUNTRY
.,O
By,O
June,DATE
21,NUMBER
.,O
2020,DATE
.,O
Brazil,COUNTRY
was,O
the,O
second,ORDINAL
country,O
in,O
number,O
of,O
confirmed,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
reporting,O
over,O
a,O
million,NUMBER
cases,O
of,O
confirmed,O
COVID,O
‐,O
19,NUMBER
and,O
our,O
analysis,O
included,O
approximately,O
a,DURATION
quarter,DURATION
of,O
these,O
cases,O
.,O
As,O
in,O
different,O
parts,O
of,O
the,O
world,O
.,O
a,O
higher,O
preva,O
‐,O
lence,O
in,O
men,O
and,O
people,O
aged,O
60,DURATION
years,DURATION
or,O
in,O
elderly,O
people,O
were,O
found,O
among,O
deaths,O
by,O
COVID,O
‐,O
199,NUMBER
‐,O
11,NUMBER
.,O
We,O
found,O
that,O
4.8,PERCENT
%,PERCENT
of,O
COVID,O
‐,O
19,NUMBER
patients,O
were,O
admitted,O
to,O
ICU,O
.,O
a,O
percentage,O
comparable,O
with,O
a,O
previous,O
study,O
conducted,O
in,O
the,O
United,COUNTRY
States,COUNTRY
of,COUNTRY
America,COUNTRY
(,O
USA,COUNTRY
),O
that,O
analyzed,O
74.439,NUMBER
COVID,O
‐,O
19,NUMBER
patients,O
.,O
among,O
whom,O
1.4,PERCENT
%,PERCENT
re,O
‐,O
quired,O
ICU12,O
.,O
Data,O
collected,O
from,O
138,NUMBER
patients,O
in,O
China,COUNTRY
showed,O
that,O
26,PERCENT
%,PERCENT
were,O
admitted,O
to,O
ICUs13,O
.,O
Thus,O
.,O
States,O
such,O
as,O
Rio,O
de,O
Janeiro,PERSON
and,O
Minas,ORGANIZATION
Gerais,ORGANIZATION
.,O
with,O
the,O
highest,O
hospitalization,O
per,O
‐,O
centages,O
in,O
the,O
country,O
(,O
23.3,PERCENT
%,PERCENT
and,O
19.6,PERCENT
%,PERCENT
.,O
respectively,O
),O
.,O
should,O
strengthen,O
measures,O
to,O
avoid,O
the,O
collapse,O
of,O
their,O
hospitals,O
in,O
‐,O
tensive,O
care,O
units,O
.,O
By,O
June,DATE
21,DATE
.,DATE
2020,DATE
.,O
Brazil,COUNTRY
has,O
exceeded,O
50.000,NUMBER
deaths,O
.,O
a,O
mark,O
.,O
so,O
far,O
.,O
reached,O
by,O
only,O
two,NUMBER
countries,O
worldwide,O
.,O
Considering,O
that,O
.,O
Rio,CITY
de,CITY
Janeiro,CITY
.,O
Para,O
.,O
Sao,CITY
Paulo,CITY
.,O
Pernambuco,LOCATION
.,O
and,O
Amazonas,PERSON
.,O
which,O
present,DATE
higher,O
percentages,O
than,O
that,O
calcu,O
‐,O
lated,O
for,O
the,O
overall,O
country,O
.,O
represent,O
a,O
great,O
national,O
con,O
‐,O
cern,O
.,O
When,O
dealing,O
with,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
.,O
mortality,O
.,O
as,O
well,O
as,O
establishing,O
priorities,O
for,O
controlling,O
it,O
.,O
is,O
the,O
most,O
impor,O
‐,O
tant,O
concern,O
.,O
Chronic,O
heart,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
as,O
the,O
most,O
prevalent,O
co,O
‐,O
morbidities,O
among,O
deaths,O
by,O
COVID,O
‐,O
19,NUMBER
in,O
Brazil,COUNTRY
State,O
of,O
Brazil,COUNTRY
.,O
until,O
May,DATE
20,DATE
.,DATE
2020,DATE
.,O
Prevalence,O
of,O
>,O
60,DURATION
years,DURATION
>,O
60,DURATION
years,DURATION
comor,O
‐,O
bidities,O
among,O
deaths,O
Source,O
:,O
The,O
epidemiological,O
and,O
clinical,O
profiles,O
of,O
confirmed,O
and,O
deaths,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
were,O
obtained,O
through,O
the,O
bulletin,O
information,O
on,O
the,O
epidemiological,O
situation,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
which,O
each,O
Brazilian,NATIONALITY
State,O
makes,O
available,O
on,O
its,O
official,O
websites,O
.,O
ICUs,O
=,O
Patients,O
admitted,O
to,O
intensive,O
care,O
units,O
;,O
95,PERCENT
%,PERCENT
CI,O
=,O
95,PERCENT
%,PERCENT
confidence,O
interval,O
;,O
N.S.,STATE_OR_PROVINCE
=,O
Not,RELIGION
specified,RELIGION
.,O
AC,O
(,O
Acre,O
),O
;,O
AL,STATE_OR_PROVINCE
(,O
Alagoas,LOCATION
),O
;,O
AP,ORGANIZATION
(,O
Amapa,CITY
),O
;,O
AM,O
(,O
Amazonas,O
),O
;,O
BA,O
(,O
Bahia,LOCATION
),O
;,O
CE,O
(,O
Ceara,LOCATION
),O
;,O
DF,O
(,O
Distrito,ORGANIZATION
Federal,ORGANIZATION
),O
;,O
ES,O
(,O
Espirito,ORGANIZATION
Santo,ORGANIZATION
),O
;,O
GO,O
(,O
Goias,CITY
),O
;,O
MA,STATE_OR_PROVINCE
(,O
Maranhao,LOCATION
),O
;,O
MT,STATE_OR_PROVINCE
(,O
Mato,ORGANIZATION
Grosso,ORGANIZATION
),O
;,O
MS,STATE_OR_PROVINCE
(,O
Mato,PERSON
Grosso,PERSON
do,O
Sul,O
),O
;,O
MG,O
(,O
Mi,O
‐,O
nas,ORGANIZATION
Gerais,ORGANIZATION
),O
;,O
PA,STATE_OR_PROVINCE
(,O
Para,O
),O
;,O
PB,O
(,O
Paraiba,LOCATION
),O
;,O
PR,STATE_OR_PROVINCE
(,O
Parana,CITY
),O
;,O
PE,STATE_OR_PROVINCE
(,O
Pernambu,O
‐,O
co,O
),O
;,O
PI,O
(,O
Piaui,LOCATION
),O
;,O
RJ,PERSON
(,O
Rio,CITY
de,CITY
Janeiro,CITY
),O
;,O
RN,O
(,O
Rio,CITY
Grande,CITY
do,O
Norte,O
),O
;,O
RS,O
(,O
Rio,CITY
Grande,CITY
do,O
Sul,O
),O
;,O
RO,O
(,O
Rondonia,LOCATION
),O
;,O
RR,O
(,O
Roraima,LOCATION
),O
;,O
SC,STATE_OR_PROVINCE
(,O
Santa,CITY
Catarina,O
),O
;,O
SP,O
(,O
Sao,CITY
Paulo,CITY
),O
.,O
SE,O
(,O
Sergipe,LOCATION
),O
;,O
TO,O
(,O
Tocantins,CITY
),O
.,O
The,O
ca,O
‐,O
pacity,O
of,O
the,O
healthcare,O
system,O
thus,O
becomes,O
a,O
major,O
issue,O
.,O
espe,O
‐,O
cially,O
considering,O
that,O
the,O
number,O
of,O
confirmed,O
cases,O
in,O
communi,O
‐,O
ties,O
is,O
rapidly,O
increasing,O
.,O
as,O
is,O
the,O
case,O
in,O
Brazil,COUNTRY
.,O
The,O
pooled,O
prevalence,O
of,O
comorbidities,O
in,O
deaths,O
by,O
COVID,O
‐,O
19,NUMBER
in,O
Brazil,COUNTRY
was,O
83,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
CI,O
:,O
79,NUMBER
87,NUMBER
),O
.,O
Previous,O
studies,O
conducted,O
in,O
Korea,COUNTRY
(,O
90.7,PERCENT
%,PERCENT
),O
and,O
China,COUNTRY
(,O
68.2,PERCENT
%,PERCENT
),O
warned,O
about,O
a,O
higher,O
prevalence,O
of,O
se,O
‐,O
vere,O
acute,O
respiratory,O
syndrome,O
caused,O
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
among,O
pa,O
‐,O
tients,O
with,O
comorbidities11,O
.14,O
.,O
They,O
also,O
point,O
hypertension,CAUSE_OF_DEATH
.,O
cardiovascular,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
.,O
and,O
diabetes,CAUSE_OF_DEATH
as,O
the,O
main,O
comorbidities,O
among,O
deaths,O
by,O
the,O
disease,CAUSE_OF_DEATH
.,O
Several,O
Deaths,O
by,O
studies,O
suggest,O
that,O
hypertension,CAUSE_OF_DEATH
is,O
the,O
most,O
common,O
comorbidity,O
in,O
COVID,O
‐,O
19,NUMBER
pa,O
‐,O
tients15,O
.,O
Likewise,O
.,O
a,O
metaanalysis,O
carried,O
out,O
recently,DATE
by,O
our,O
team,O
showed,O
that,O
hypertension,CAUSE_OF_DEATH
is,O
the,O
most,O
prevalent,O
comorbidity,O
among,O
deaths,O
from,O
COVID,O
‐,O
19,NUMBER
.,O
followed,O
by,O
diabetes,CAUSE_OF_DEATH
and,O
chronic,O
heart,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
ranking,O
third16,O
.,O
Now,DATE
.,O
in,O
Brazil,COUNTRY
we,O
found,O
that,O
the,O
main,O
comorbidities,O
among,O
deaths,O
are,O
chronic,O
heart,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
and,O
diabetes,CAUSE_OF_DEATH
.,O
The,O
third,ORDINAL
most,O
common,O
comorbidity,O
were,O
the,O
chronic,O
lung,O
diseases,CAUSE_OF_DEATH
.,O
followed,O
by,O
chronic,O
kidney,O
diseases,CAUSE_OF_DEATH
.,O
stroke,O
.,O
hyperten,O
‐,O
sion,O
.,O
obesity,O
and,O
immunosuppressive,O
diseases,CAUSE_OF_DEATH
which,O
may,O
include,O
HIV,CAUSE_OF_DEATH
infection,CAUSE_OF_DEATH
and,O
organ,O
transplant,O
patients,O
.,O
Pachiega,O
et,O
al,O
.,O
due,O
to,O
COVID,O
‐,O
19,NUMBER
from,O
May,DATE
9,DATE
to,O
20,NUMBER
.,O
2020,DATE
in,O
Brazil,COUNTRY
.,O
Chronic,O
Heart,O
Diseases,CAUSE_OF_DEATH
Chronic,O
Lung,O
Diseases,CAUSE_OF_DEATH
Chronic,O
Kidney,O
Diseases,CAUSE_OF_DEATH
Immunosup,O
‐,O
pressive,O
Diseases,CAUSE_OF_DEATH
Chronic,O
Liver,CAUSE_OF_DEATH
Diseases,CAUSE_OF_DEATH
Digestive,O
System,O
Dis,O
‐,O
eases,O
Hematological,O
diseases,CAUSE_OF_DEATH
Metabolic,O
Diseases,CAUSE_OF_DEATH
Smoking,CAUSE_OF_DEATH
habit,O
Source,O
:,O
Clinical,O
profiles,O
of,O
confirmed,O
and,O
deaths,O
cases,O
by,O
COVID,O
‐,O
19,NUMBER
.,O
were,O
obtained,O
through,O
the,O
bulletin,O
information,O
about,O
the,O
epidemiological,O
situation,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
which,O
each,O
Brazilian,NATIONALITY
state,O
makes,O
available,O
on,O
its,O
official,O
websites,O
.,O
The,O
epidemiolog,O
‐,O
ical,O
bulletins,O
of,O
each,O
State,O
do,O
not,O
specify,O
what,O
were,O
the,O
chronic,O
heart,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
of,O
patients,O
who,O
died,O
from,O
COVID,O
‐,DATE
19,DATE
.,O
although,O
this,O
group,O
may,O
include,O
patients,O
with,O
coronary,O
heart,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
.,O
arrhyth,O
‐,O
mias,O
.,O
infarction,O
.,O
patients,O
with,O
pacemakers,O
and,O
others,O
.,O
Our,O
re,O
‐,O
sults,O
showed,O
that,O
this,O
group,O
of,O
comorbidities,O
was,O
the,O
most,O
impor,O
‐,O
tant,O
in,O
the,O
population,O
studied,O
.,O
and,O
this,O
is,O
an,O
important,O
finding,O
.,O
because,O
the,O
Ministry,ORGANIZATION
of,ORGANIZATION
Health,ORGANIZATION
defends,O
the,O
use,O
of,O
hydroxychloro,O
‐,O
quine,O
for,O
treating,O
COVID,O
‐,O
19,NUMBER
.,O
A,O
recent,O
study,O
claims,O
that,O
some,O
cardiac,O
manifestations,O
.,O
such,O
as,O
cardiac,O
arrhythmias,O
.,O
and,O
even,O
conduction,O
disorders,O
without,O
repercussion,O
.,O
may,O
represent,O
the,O
ini,O
‐,O
tial,O
manifestations,O
of,O
toxicity,O
related,O
to,O
chloroquine,O
or,O
hydrox,O
‐,O
ychloroquine17,O
.,O
Therefore,O
.,O
the,O
use,O
of,O
these,O
drugs,CRIMINAL_CHARGE
can,O
lead,O
to,O
se,O
‐,O
rious,O
complications,CAUSE_OF_DEATH
and,O
even,O
death,O
in,O
patients,O
with,O
previous,O
heart,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
.,O
On,O
the,O
other,O
hand,O
.,O
the,O
use,O
of,O
these,O
drugs,CRIMINAL_CHARGE
as,O
post,O
exposure,O
prophylaxis,O
(,O
PEP,O
),O
.,O
has,O
also,O
proved,O
unsuccessful18,O
.,O
Some,O
difficulties,O
to,O
develop,O
this,O
study,O
were,O
found,O
.,O
Firstly,O
.,O
not,O
ev,O
‐,O
ery,ORGANIZATION
Health,ORGANIZATION
Department,ORGANIZATION
updates,O
their,O
epidemiological,O
bulletins,O
daily,SET
.,O
so,O
the,O
updating,O
of,O
data,O
on,O
a,O
daily,SET
basis,O
was,O
unfeasible,O
.,O
Secondly,O
.,O
the,O
epidemiological,O
bulletins,O
were,O
not,O
standardized,O
.,O
not,O
all,O
of,O
them,O
provide,O
epidemiological,O
data,O
such,O
as,O
age,O
.,O
nor,O
clinical,O
data,O
such,O
as,O
the,O
presence,O
of,O
comorbidities,O
.,O
which,O
im,O
‐,O
paired,O
the,O
collection,O
of,O
complete,O
data,O
.,O
Thirdly,O
.,O
many,O
epidemio,O
‐,O
logical,O
bulletins,O
provide,O
information,O
only,O
as,O
graphics,O
and,O
the,O
absolute,O
numbers,O
were,O
lacking,O
.,O
hampering,O
data,O
replication,O
.,O
Final,O
‐,O
ly,O
.,O
each,O
Secretariat,ORGANIZATION
reported,O
different,O
age,O
groups,O
.,O
which,O
im,O
‐,O
paired,O
the,O
comparisons,O
among,O
them,O
.,O
We,O
concluded,O
that,O
there,O
is,O
a,O
high,O
prevalence,O
of,O
comorbidities,O
among,O
deaths,O
by,O
COVID,O
‐,O
19,NUMBER
.,O
af,O
‐,O
fecting,O
mainly,O
men,O
aged,O
over,O
60,DURATION
years,DURATION
.,O
The,O
group,O
of,O
chronic,O
heart,O
diseases,CAUSE_OF_DEATH
and,O
diabetes,CAUSE_OF_DEATH
were,O
the,O
main,O
comorbidities,O
among,O
these,O
pa,O
‐,O
tients,O
and,O
this,O
is,O
relevant,O
considering,O
the,O
possible,O
adverse,O
ef,O
‐,O
fects,O
produced,O
by,O
drugs,CRIMINAL_CHARGE
such,O
as,O
hydroxychloroquine,O
.,O
On,O
the,O
other,O
hand,O
.,O
we,O
recommend,O
conducting,O
studies,O
based,O
on,O
medical,O
records,O
analyzes,O
.,O
with,O
the,O
purpose,O
of,O
knowing,O
specifically,O
the,O
proportion,O
of,O
each,O
heart,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
in,O
patients,O
affected,O
by,O
COVID,O
‐,O
19,NUMBER
.,O
Acknowl,O
‐,O
edging,O
such,O
factors,O
may,O
help,O
to,O
better,O
defining,O
the,O
risks,O
of,O
death,O
among,O
these,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
enabling,O
a,O
more,O
targeted,O
and,O
specific,O
approach,O
to,O
avoid,O
probable,O
deaths,O
.,O
In,O
a,O
scenario,O
without,O
effective,O
antivirals,O
or,O
vaccines,O
available,O
.,O
governments,O
should,O
apply,O
continuous,O
countermeasures,O
for,O
different,O
pandemic,O
situa,O
‐,O
tions,O
to,O
reduce,O
mortality,O
.,O
especially,O
in,O
States,LOCATION
with,O
high,O
per,O
‐,O
centages,O
of,O
ICU,O
hospitalization,O
and,O
deaths,O
.,O
AUTHORS,O
CONTRIBU,O
‐,O
TIONS,O
JP,O
.,O
AJSA,ORGANIZATION
.,O
GTS,O
.,O
BTA,ORGANIZATION
.,O
MSMA,ORGANIZATION
and,O
FGL,O
contributed,O
to,O
data,O
col,O
‐,O
lection,O
and,O
analysis,O
.,O
and,O
drafting,O
the,O
first,ORDINAL
version,O
conception,O
and,O
design,O
.,O
data,O
analysis,O
and,O
interpretation,O
.,O
themselves,O
respon,O
‐,O
sible,O
for,O
all,O
aspects,O
of,O
the,O
work,O
.,O
guaranteeing,O
their,O
accuracy,O
and,O
integrity,O
.,O
CONFLICT,O
OF,O
INTERESTS,O
1,NUMBER
.,O
World,O
Health,O
Organiza,O
‐,O
tion,O
.,O
Coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
:,O
situation,O
report,O
124,NUMBER
.,O
[,O
cited,O
2020,DATE
Jun,DATE
22,DATE
],O
.,O
2,NUMBER
.,O
Gorbalenya,ORGANIZATION
AE,ORGANIZATION
.,O
Baker,PERSON
SC,STATE_OR_PROVINCE
.,O
Baric,PERSON
RS,O
.,O
de,O
Groot,O
RJ,O
.,O
Drosten,PERSON
C,O
.,O
Gulyaeva,O
AA,O
.,O
et,O
al,O
.,O
The,O
species,O
severe,O
acute,O
respiratory,O
Chronic,O
heart,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
as,O
the,O
most,O
prevalent,O
comor,O
‐,O
bidities,O
among,O
deaths,O
by,O
COVID,O
‐,O
19,NUMBER
in,O
Brazil,COUNTRY
syndrome,O
‐,O
related,O
coronavirus,O
:,O
classifying,O
2019,DATE
‐,O
nCoV,O
and,O
11,NUMBER
.,O
Korean,NATIONALITY
Society,O
of,O
In,O
‐,O
fectious,O
Diseases,CAUSE_OF_DEATH
.,O
Korea,ORGANIZATION
Centers,ORGANIZATION
for,O
naming,O
it,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Nat,PERSON
Microbiol,O
.,O
2020,DATE
;,O
5:536,NUMBER
‐,O
44,NUMBER
.,O
Disease,ORGANIZATION
Control,ORGANIZATION
and,ORGANIZATION
Prevention,ORGANIZATION
.,O
Analy,O
‐,O
sis,O
on,O
54,NUMBER
mortality,O
3,NUMBER
.,O
Chan,RELIGION
JF,O
.,O
Yuan,PERSON
S,PERSON
.,O
Kok,PERSON
KH,O
.,O
To,ORGANIZATION
KK,ORGANIZATION
.,O
Chu,PERSON
H,PERSON
.,O
Yang,PERSON
J,PERSON
.,O
et,O
al,O
.,O
A,O
familial,O
cluster,O
of,O
pneumonia,CAUSE_OF_DEATH
associated,O
with,O
the,O
2019,DATE
novel,O
from,O
January,DATE
19,DATE
to,O
March,DATE
10,DATE
.,DATE
2020,DATE
.,O
J,O
Korean,NATIONALITY
Med,O
Sci,O
.,O
coronavirus,O
indicatingperson,O
‐,O
to,O
‐,O
person,O
transmission,O
:,O
a,O
study,O
of,O
a,O
family,O
cluster,O
.,O
Lancet,O
.,O
2020,DATE
;,O
395:514,NUMBER
‐,O
23,NUMBER
.,O
4,NUMBER
.,O
Cai,PERSON
H.,PERSON
Sex,O
difference,O
and,O
smoking,CAUSE_OF_DEATH
predisposition,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
Lancet,O
Respir,O
Med,O
.,O
2020,DATE
;,O
8,NUMBER
:,O
e20,O
.,O
5,NUMBER
.,O
Chen,O
N,O
.,O
Zhou,PERSON
M,PERSON
.,O
Dong,PERSON
X,O
.,O
Qu,O
J,O
.,O
Gong,O
F,O
.,O
Han,O
Y,O
.,O
et,O
al,O
.,O
Epidemiological,O
and,O
clinical,O
characteristics,O
of,O
99,NUMBER
cases,O
of,O
2019,DATE
novel,O
coronavirus,O
pneumonia,CAUSE_OF_DEATH
in,O
Wuhan,CITY
.,O
China,COUNTRY
:,O
a,O
descriptive,O
study,O
.,O
Lancet,O
.,O
2020,DATE
;,O
395:507,NUMBER
‐,O
13,NUMBER
.,O
6,NUMBER
.,O
Wang,PERSON
D,PERSON
.,O
Hu,O
B,O
.,O
Hu,O
C,O
.,O
Zhu,PERSON
F,PERSON
.,O
Liu,PERSON
X,PERSON
.,O
Zhang,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Clinical,O
characteristics,O
of,O
138,NUMBER
hospitalized,O
patients,O
with,O
2019,DATE
novel,O
coronavirus,O
‐,O
infected,O
pneumonia,CAUSE_OF_DEATH
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
JAMA,ORGANIZATION
.,O
7,NUMBER
.,O
Yang,PERSON
J,PERSON
.,O
Zheng,O
Y,O
.,O
Gou,PERSON
X,PERSON
.,O
Pu,PERSON
K,PERSON
.,O
Chen,PERSON
Z,PERSON
.,O
Guo,PERSON
Q,O
.,O
et,O
al,O
.,O
Prevalence,O
of,O
comor,O
‐,O
bidities,O
and,O
its,O
effects,O
in,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
8,DATE
.,O
Brasil,O
.,O
Ministrio,PERSON
da,PERSON
Sade,PERSON
.,O
Secretaria,O
de,O
Vigilncia,O
em,O
Sade,O
.,O
12,NUMBER
.,O
CDC,ORGANIZATION
COVID,O
‐,O
19,NUMBER
Response,O
Team,O
.,O
Preliminary,O
estimates,O
of,O
the,O
prevalence,O
of,O
selected,O
underlying,O
health,O
conditions,O
among,O
patients,O
with,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
‐,O
United,COUNTRY
States,COUNTRY
.,O
February,DATE
12,DATE
‐,O
March,DATE
28,DATE
.,O
2020,DATE
.,O
MMWR,O
Morb,O
Mortal,O
Wkly,O
13,NUMBER
.,O
Wang,PERSON
D,PERSON
.,O
Hu,O
B,O
.,O
Hu,O
C,O
.,O
Zhu,PERSON
F,O
.,O
Liu,PERSON
X,PERSON
.,O
Zhang,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Clinical,O
characteristics,O
of,O
138,NUMBER
hospitalized,O
pa,O
‐,O
tients,O
with,O
2019,DATE
novel,O
coronavirus,O
‐,O
infected,O
pneumonia,CAUSE_OF_DEATH
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
JAMA,ORGANIZATION
.,O
14,NUMBER
.,O
Du,O
Y,O
.,O
Tu,PERSON
L,PERSON
.,O
Zhu,PERSON
P,O
.,O
Mu,O
M,O
.,O
Wang,PERSON
R,PERSON
.,O
Yang,PERSON
P,O
.,O
et,O
al,O
.,O
Clinical,O
features,O
of,O
85,NUMBER
fatal,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
from,O
Wuhan,CITY
:,O
a,O
retrospective,O
observational,O
study,O
.,O
Am,O
J,O
Respir,O
Crit,O
Care,O
Med,O
.,O
15,NUMBER
.,O
Wang,PERSON
B,PERSON
.,O
Li,PERSON
R,PERSON
.,O
Lu,PERSON
Z,PERSON
.,O
Huang,PERSON
Y.,O
Does,O
comorbidity,O
increase,O
the,O
risk,O
of,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
:,O
evidence,O
from,O
meta,O
‐,O
analysis,O
.,O
Ag,O
‐,O
ing,O
(,O
Albany,CITY
NY,STATE_OR_PROVINCE
),O
.,O
2020,DATE
;,O
12:6049,NUMBER
‐,O
57,NUMBER
.,O
Boletim,PERSON
Epidemiolgico,PERSON
Especial,PERSON
COE,O
‐,O
COVID19,O
.,O
Braslia,O
:,O
16,NUMBER
.,O
Espinosa,ORGANIZATION
OA,ORGANIZATION
.,O
Zanetti,PERSON
AS,STATE_OR_PROVINCE
.,O
Antunes,PERSON
EF,O
.,O
Longhi,PERSON
FG,PERSON
.,O
Matos,ORGANIZATION
TA,ORGANIZATION
.,O
Ministrio,ORGANIZATION
da,ORGANIZATION
Sade,ORGANIZATION
;,O
2020,DATE
.,O
[,O
cited,O
2020,DATE
Jun,PERSON
22,NUMBER
],O
.,O
Available,O
Battaglini,PERSON
PF,O
.,O
Prevalence,O
of,O
comorbidities,O
in,O
pa,O
‐,O
tients,O
and,O
9,NUMBER
.,O
Du,PERSON
RH,PERSON
.,O
Liu,ORGANIZATION
LM,ORGANIZATION
.,O
Yin,PERSON
W,PERSON
.,O
Wang,PERSON
W,PERSON
.,O
Guan,O
LL,O
.,O
Yuan,O
ML,O
.,O
et,O
al,O
.,O
17,NUMBER
.,O
Chatre,O
C,O
.,O
Roubille,O
F,O
.,O
Vernhet,O
H,O
.,O
Jorgensen,PERSON
C,O
.,O
Pers,O
YM,O
.,O
Hospitalization,O
and,O
critical,O
care,O
of,O
109,NUMBER
decedents,O
with,O
Cardiac,O
complications,CAUSE_OF_DEATH
attributed,O
to,O
chloroquine,O
and,O
COVID,O
‐,O
19,NUMBER
pneumonia,CAUSE_OF_DEATH
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
Ann,PERSON
Am,PERSON
Thorac,PERSON
Soc,PERSON
.,O
2020,DATE
In,O
Press,O
.,O
Drug,O
Saf,O
.,O
2018,DATE
;,O
41:919,NUMBER
‐,O
31,NUMBER
.,O
10,NUMBER
.,O
Chen,O
T,O
.,O
Dai,PERSON
Z,PERSON
.,O
Mo,PERSON
P,PERSON
.,O
Li,PERSON
X,PERSON
.,O
Ma,O
Z,O
.,O
Song,O
S,O
.,O
et,O
al,O
.,O
Clinical,O
18,NUMBER
.,O
Boulware,PERSON
DR,PERSON
.,O
Pullen,PERSON
MF,PERSON
.,O
Bangdiwala,ORGANIZATION
AS,ORGANIZATION
.,O
Pastick,PERSON
KA,O
.,O
characteristics,O
and,O
outcomes,O
of,O
older,O
patients,O
with,O
coron,O
‐,O
avirus,O
Lofgren,ORGANIZATION
SM,ORGANIZATION
.,O
Okafor,ORGANIZATION
EC,ORGANIZATION
.,O
et,O
al,O
.,O
A,O
randomized,O
trial,O
of,O
dis,O
‐,O
ease,O
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
in,O
Wuhan,CITY
.,O
China,COUNTRY
(,O
2019,DATE
),O
:,O
a,O
single,O
‐,O
hydroxy,O
‐,O
chloroquine,O
as,O
postexposure,O
prophylaxis,O
for,O
Covid,O
‐,O
19,NUMBER
.,O
centered,O
.,O
retrospective,O
study,O
.,O
J,PERSON
Gerontol,PERSON
A,PERSON
Biol,PERSON
Sci,PERSON
Med,PERSON
Sci,PERSON
.,O
N,O
Engl,PERSON
J,PERSON
Med,O
.,O
2020,DATE
In,O
Press,O
.,O
2020,DATE
:,O
glaa089,NUMBER
In,O
Press,O
.,O
